List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Beta Pharma Inc
Eli Lilly and Co
G1 Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
MEI Pharma Inc
MetaMax Ltd
Novartis AG
Onconova Therapeutics Inc
Pfizer Inc
Sihuan Pharmaceutical Holdings Group Ltd
Sino Biopharmaceutical Ltd
Teijin Pharma Ltd
Tiziana Life Sciences Plc
ViroStatics srl
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BEBT-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-1178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GZ-381 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HEC-80797 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lerociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMD-37K - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-123300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-6390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TQ-05510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trilaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voruciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS.-2370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-3287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2018: MEI Pharma to present preclinical data of Voruciclib in combination with Venetoclax at ASH 2018
Oct 23, 2018: Targeted drug could extend lives of some women with advanced breast cancer
Oct 22, 2018: Pfizer's palbociclib increases overall survival in breast cancer patients
Oct 21, 2018: G1 Therapeutics presents additional data from randomized phase 2 trial of Trilaciclib in combination with Etoposide/Carboplatin for treatment of first-line small cell lung cancer
Oct 16, 2018: Tiziana Life Sciences presents data from animal studies demonstrating the potential synergistic activity of Milciclib with tyrosine kinase inhibitors to treat Hepatocellular Carcinoma (HCC) at the American Association for the Study of Liver Diseases (AASLD)
Oct 09, 2018: G1 Therapeutics to present additional data from randomized phase 2 trial of Trilaciclib in combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress
Oct 03, 2018: EU nod for Lilly's new breast cancer drug
Sep 17, 2018: G1 Therapeutics to report Myelopreservation data from randomized phase 2 trial of Trilaciclib/Chemotherapy/Tecentriq in Small Cell Lung Cancer in Fourth Quarter 2018
Sep 13, 2018: G1 Therapeutics announces appointment of Garry Nicholson to Board of Directors
Aug 07, 2018: Pfizer's breakthrough innovative drug IBRANCE (palbociclib) receives approval in China
Jul 26, 2018: Lilly receives CHMP's positive opinion for Verzenios
Jul 18, 2018: FDA approves expanded indication for Novartis drug Kisqali
Jul 09, 2018: TRIO Awarded NATALEE Study, Largest Single Phase III Breast Cancer Clinical Trial in its History
Jun 25, 2018: Pfizer unveils new results from PALOMA-3 trial for breast cancer
Jun 04, 2018: Results from AstraZeneca Study Presented at ASCO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..3), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Companies, H2 2018 (Contd..5), H2 2018
Products under Development by Companies, H2 2018 (Contd..6), H2 2018
Products under Development by Companies, H2 2018 (Contd..7), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Beta Pharma Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by G1 Therapeutics Inc, H2 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018
Pipeline by MEI Pharma Inc, H2 2018
Pipeline by MetaMax Ltd, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Onconova Therapeutics Inc, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H2 2018
Pipeline by Sino Biopharmaceutical Ltd, H2 2018
Pipeline by Teijin Pharma Ltd, H2 2018
Pipeline by Tiziana Life Sciences Plc, H2 2018
Pipeline by ViroStatics srl, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Companies Mentioned
• Beta Pharma Inc
• Eli Lilly and Co
• G1 Therapeutics Inc
• Jiangsu Hengrui Medicine Co Ltd
• MEI Pharma Inc
• MetaMax Ltd
• Novartis AG
• Onconova Therapeutics Inc
• Pfizer Inc
• Sihuan Pharmaceutical Holdings Group Ltd
• Sino Biopharmaceutical Ltd
• Teijin Pharma Ltd
• Tiziana Life Sciences Plc
• ViroStatics srl